Budget Impact Analysis of <i>EGFR</i> Mutation Liquid Biopsy for First- and Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer in Greece

Budget Impact Analysis of <i>EGFR</i> Mutation Liquid Biopsy for First- and Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer in Greece

Within the European Union, Greece has the highest incidence of lung cancer among people under 45 years of age. Epidermal growth factor receptor (<i>EGFR</i>) tyrosine kinase inhibitors are indicated for the treatment of patients with <i>EGFR</i> mutation-positive metastatic n...

Full description

Bibliographic Details
Main Authors:	Mindy Cheng, Athanasios Akalestos, Sidney Scudder
Format:	Article
Language:	English
Published:	MDPI AG 2020-06-01
Series:	Diagnostics
Subjects:	budget impact cost epidermal growth factor receptor (<i>EGFR</i>) plasma biopsy non-small cell lung cancer (NSCLC) companion diagnostic
Online Access:	https://www.mdpi.com/2075-4418/10/6/429

Similar Items

Liquid Biopsy in <i>EGFR</i>-Mutated Advanced NSCLC from T790M to <i>MET</i> Amplification: Clinical Implications and Possibilities in the Resistance Setting
by: Luigi Della Gravara, et al.
Published: (2023-04-01)

Detection of <i>EGFR</i> Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR
by: Annamaria Siggillino, et al.
Published: (2020-12-01)

Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
by: Alessandro Leonetti, et al.
Published: (2021-06-01)

Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR‐mutated lung adenocarcinoma
by: Anahí Castañeda‐Zárraga, et al.
Published: (2020-11-01)

Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer
by: Martin Pesta, et al.
Published: (2022-07-01)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
by: Yuko Oya, et al.
Published: (2021-01-01)

Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports
by: Loc Carlo Bao, et al.
Published: (2024-03-01)

Non-Small Cell Lung Cancer Harboring Concurrent <i>EGFR</i> Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma
by: Valerio Gristina, et al.
Published: (2021-06-01)

Hydroxygenkwanin Suppresses Non-Small Cell Lung Cancer Progression by Enhancing EGFR Degradation
by: Yann-Lii Leu, et al.
Published: (2020-02-01)

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
by: William Tompkins, MD, et al.
Published: (2024-08-01)

Targeting <i>BRAF</i> Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
by: Frank Aboubakar Nana, et al.
Published: (2021-09-01)

Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
by: Jason S. Agulnik, et al.
Published: (2022-02-01)

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
by: Veldore VH, et al.
Published: (2018-01-01)

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
by: Bing Wei, et al.
Published: (2019-05-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
by: Yongkang Bai, et al.
Published: (2023-04-01)

Concordance of Abundance for Mutational <i>EGFR</i> and Co-Mutational <i>TP53</i> with Efficacy of <i>EGFR</i>-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer
by: Youping Wang, et al.
Published: (2023-09-01)

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report
by: Markus Falk, et al.
Published: (2023-09-01)

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
by: Hsu-Yuan Chen, et al.
Published: (2024-10-01)

When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan
by: Chieh-Lung Chen, et al.
Published: (2022-05-01)

Real-World Clinical Outcomes for Patients with <i>EGFR</i> and <i>HER2</i> Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
by: Kelly Li, et al.
Published: (2023-07-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
by: Tia Cheunkarndee, BA, et al.
Published: (2024-06-01)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
by: Hyun Ae Jung, et al.
Published: (2020-10-01)

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer
by: Rodolfo Chicas-Sett, et al.
Published: (2023-01-01)

Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
by: Stefano Mariani, et al.
Published: (2022-04-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
by: Jae Cheol Lee, et al.
Published: (2021-05-01)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
by: Jinyao Zhang, et al.
Published: (2021-12-01)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
by: Antonio Passaro, et al.
Published: (2021-07-01)

Performance of the Oncomine<sup>TM</sup> Lung cfDNA Assay for Liquid Biopsy by NGS of NSCLC Patients in Routine Laboratory Practice
by: Giuseppa De Luca, et al.
Published: (2020-04-01)

EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)
by: Vázquez S, et al.
Published: (2016-02-01)

EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
by: Jeng-Shiuan Tsai, et al.
Published: (2021-09-01)

EGFR‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs: A meta‐analysis
by: Thang Thanh Phan, et al.
Published: (2022-08-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
by: Yuankai Shi, et al.
Published: (2023-01-01)

Detection of clinically-relevant <em>EGFR</em> variations in <em>de novo</em> small cell lung carcinoma by droplet digital PCR
by: Rajesh Venkataram, et al.
Published: (2022-09-01)

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
by: Stephen V. Liu, et al.
Published: (2023-09-01)

Clinical Impact of two Different Diagnostic Strategies in the First- and Second-Line Treatment of Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
by: Giovanni Gancitano, et al.
Published: (2020-02-01)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
by: Haosheng Zheng, et al.
Published: (2024-01-01)

FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in <i>EGFR</i>-Mutant NSCLC Cells
by: Jingwen Feng, et al.
Published: (2022-01-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
by: Li Liu, et al.
Published: (2021-10-01)

The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI
by: Phan TT, et al.
Published: (2018-11-01)